Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8471824 | Immuno-analyse & Biologie Spécialisée | 2007 | 6 Pages |
Abstract
B-Chronic lymphocytic leukaemia (CLL) is the most frequent of chronic leukaemias. It is defined by a durable absolute lymphocytosis (>Â 4Â ÃÂ 109/l) with small mature lymphoid cells in the peripheral blood. Immunological score established on five criterias (positivity of CD5 and CD23, negativity of the FMC7 and weak expression of sIg and CD22 or CD79b) is four or five. The Binet classification defines three stages of different evolution: the stage A (65% of the cases) and B (28%) without or with three areas involved at least, in the absence of anaemia or thrombopenia and the stage C with anaemia (haemoglobin lower than 10Â g/dl) or thrombopenia (platelets lower than 100Â ÃÂ 109/l). Patients with stage A will a few progress quickly and conversely others will remain stable with no evolution for very long periods. Four markers with prognosis value were recently identified and allow to adopt new therapeutic strategies according to the presence or not of these markers. These factors are lymphocytes doubling time, serum thymidine kinase, cytogenetic abnormalities including del(11) and del(17), +12 and del(13), and the immunoglobulin mutational profile. The therapeutic strategies evolved these last years and call, if criteria of gravity are present, to chemotherapy (purines analogs associated or not with cyclophosphamid) and immunotherapy (anti-CD20 and/or anti-CD52 monoclonal antibody).
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
X. Troussard,